Eterna Therapeutics Inc. (NASDAQ:ERNA) Short Interest Up 86.6% in February

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 348,200 shares, an increase of 86.6% from the February 13th total of 186,600 shares. Based on an average trading volume of 10,510,000 shares, the short-interest ratio is presently 0.0 days. Approximately 1.8% of the company’s shares are short sold.

Institutional Investors Weigh In On Eterna Therapeutics

An institutional investor recently raised its position in Eterna Therapeutics stock. Geode Capital Management LLC increased its position in shares of Eterna Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 257,310 shares of the company’s stock after buying an additional 236,875 shares during the period. Geode Capital Management LLC owned about 4.76% of Eterna Therapeutics worth $76,000 at the end of the most recent reporting period. Institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Price Performance

Eterna Therapeutics stock traded up $0.00 during midday trading on Friday, hitting $0.26. 176,871 shares of the stock were exchanged, compared to its average volume of 13,049,398. Eterna Therapeutics has a 1 year low of $0.22 and a 1 year high of $2.63. The firm has a market cap of $1.39 million, a P/E ratio of -0.03 and a beta of 4.47. The company has a 50 day moving average price of $0.35 and a two-hundred day moving average price of $0.71.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.